Capsulectomy Shunt Revision versus Repeat Shunt Implantation Following Ahmed Glaucoma Valve Failure in Refractory Glaucoma. 2023

Shahin Yazdani, and Azadeh Doozandeh, and Farideh Sharifipour, and Kiana Hassanpour, and Mohammad Pakravan, and Maryam Hajizadeh, and Hamed Esfandiari, and Parisa Mohammadi
Ophthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Ocular Tissue Engineering Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

OBJECTIVE To investigate the efficacy of capsulectomy shunt revision (CSR) compared with the implantation of a second Ahmed glaucoma valve (re-AGV) in glaucoma patients with failed shunts. METHODS Quasi-experimental study. METHODS Forty-six eyes with failed Ahmed glaucoma valves (AGVs) were included in the study; 25 underwent CSR, whereas 21 underwent re-AGV. METHODS Patients were scheduled for CSR or re-AGV based on the appearance and accessibility of the existing AGV versus the feasibility for re-AGV in other quadrants. The CSR involved incision and dissection down to the thick fibrous capsule around the AGV plate, which was excised extensively. For re-AGV, the second shunt was implanted in the supranasal or infranasal quadrants. METHODS Surgical success, defined as intraocular pressure (IOP) > 5 mmHg, ≤ 21 mmHg, IOP reduction ≥ 20% from baseline, and no reoperation for glaucoma. Secondary outcome measures were IOP, number of glaucoma medications, and complications during a 12-month follow-up period. RESULTS Mean IOP was significantly lower than preoperative values at all time points in both study groups (P < 0.001). Intraocular pressure decreased significantly from 28.3 ± 5.04 mmHg at baseline to 16.4 ± 2.4 mmHg at final follow-up in the capsulectomy group (P = 0.002). Corresponding IOP values for re-AGV were 30.99 ± 6.2 and 13.6 ± 3.8 mmHg, respectively (P = 0.001). Intraocular pressure in the CSR group was higher than re-AGV during the study (P = 0.003). The cumulative probability of success at 12 months was significantly higher in the re-AGV group (87.5% vs 53.3%, P = 0.002). There was no significant difference in the number of glaucoma medications and overall complications rate between the study groups. Wound leakage was the only complication more common in the CSR group (P = 0.012). CONCLUSIONS In the eyes with a failed AGV, re-AGV and CSR are both effective. Implantation of a second shunt seems more effective than the surgical revision of an existing device; however, the latter procedure may be a viable option in selected cases. BACKGROUND The author(s) have no proprietary or commercial interest in any materials discussed in this article.

UI MeSH Term Description Entries

Related Publications

Shahin Yazdani, and Azadeh Doozandeh, and Farideh Sharifipour, and Kiana Hassanpour, and Mohammad Pakravan, and Maryam Hajizadeh, and Hamed Esfandiari, and Parisa Mohammadi
August 2019, Journal of glaucoma,
Shahin Yazdani, and Azadeh Doozandeh, and Farideh Sharifipour, and Kiana Hassanpour, and Mohammad Pakravan, and Maryam Hajizadeh, and Hamed Esfandiari, and Parisa Mohammadi
April 2019, Journal of glaucoma,
Shahin Yazdani, and Azadeh Doozandeh, and Farideh Sharifipour, and Kiana Hassanpour, and Mohammad Pakravan, and Maryam Hajizadeh, and Hamed Esfandiari, and Parisa Mohammadi
August 2019, Journal of glaucoma,
Shahin Yazdani, and Azadeh Doozandeh, and Farideh Sharifipour, and Kiana Hassanpour, and Mohammad Pakravan, and Maryam Hajizadeh, and Hamed Esfandiari, and Parisa Mohammadi
November 1997, [Zhonghua yan ke za zhi] Chinese journal of ophthalmology,
Shahin Yazdani, and Azadeh Doozandeh, and Farideh Sharifipour, and Kiana Hassanpour, and Mohammad Pakravan, and Maryam Hajizadeh, and Hamed Esfandiari, and Parisa Mohammadi
December 2000, Yan ke xue bao = Eye science,
Shahin Yazdani, and Azadeh Doozandeh, and Farideh Sharifipour, and Kiana Hassanpour, and Mohammad Pakravan, and Maryam Hajizadeh, and Hamed Esfandiari, and Parisa Mohammadi
December 2005, Korean journal of ophthalmology : KJO,
Shahin Yazdani, and Azadeh Doozandeh, and Farideh Sharifipour, and Kiana Hassanpour, and Mohammad Pakravan, and Maryam Hajizadeh, and Hamed Esfandiari, and Parisa Mohammadi
October 2021, International ophthalmology,
Shahin Yazdani, and Azadeh Doozandeh, and Farideh Sharifipour, and Kiana Hassanpour, and Mohammad Pakravan, and Maryam Hajizadeh, and Hamed Esfandiari, and Parisa Mohammadi
January 2011, Clinical ophthalmology (Auckland, N.Z.),
Shahin Yazdani, and Azadeh Doozandeh, and Farideh Sharifipour, and Kiana Hassanpour, and Mohammad Pakravan, and Maryam Hajizadeh, and Hamed Esfandiari, and Parisa Mohammadi
February 2009, Ophthalmology,
Shahin Yazdani, and Azadeh Doozandeh, and Farideh Sharifipour, and Kiana Hassanpour, and Mohammad Pakravan, and Maryam Hajizadeh, and Hamed Esfandiari, and Parisa Mohammadi
January 2020, Journal of current ophthalmology,
Copied contents to your clipboard!